Therapeutics News and Research

RSS

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor, with various factors stacking the odds against successful treatment: early detection is uncommon, it tends to spread quickly and recurrence is likely. However, several newer approaches show promise in increasing the response rate to pancreatic cancer treatment.

10 Oct 2014

BIDMC scientists uncover new class of molecules that protects against diabetes

Scientists at the Salk Institute and Beth Israel Deaconess Medical Center in Boston have discovered a new class of molecules—produced in human and mouse fat—that protects against diabetes.

10 Oct 2014

UChicago awarded $12 million grant to establish national center to study drug abuse-related behaviors

The National Institute on Drug Abuse has awarded the University of Chicago a $12 million, five year grant to establish a national Center of Excellence to study drug abuse-associated behaviors by conducting research with rats.

10 Oct 2014

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments.

9 Oct 2014

NIH announces high-risk, high-reward grants for UCSF researchers

UC San Francisco researchers received five awards announced this week by the National Institutes of Health (NIH) for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders.

8 Oct 2014

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

8 Oct 2014

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).

8 Oct 2014

UCSF researchers receive five NIH awards for high-risk scientific research projects

UC San Francisco researchers received five awards announced this week by the National Institutes of Health for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders.

8 Oct 2014

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech.

7 Oct 2014

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).

7 Oct 2014

Many US patients with liver cancer do not receive proper treatment

Many US patients with liver cancer-even those with early stage disease that can often be cured-do not receive treatment for their disease, according to an analysis of studies published between 1989 and 2013.

6 Oct 2014

FDA grants orphan drug designation for neuroblastoma vaccine

The U.S. Food and Drug Administration granted orphan drug designation for a neuroblastoma vaccine from MabVax Therapeutics, providing development incentive with market exclusivity of the novel treatment for children with this deadly childhood cancer.

6 Oct 2014

SynGen announces securement of additional financing from San Francisco-based life sciences venture capital firm

SynGen, Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has secured additional financing from Bay City Capital, LLC, a San Francisco-based life sciences venture capital firm.

6 Oct 2014

Halozyme's PEGPH20 receives FDA Orphan Drug designation for treatment of pancreatic cancer

Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.

3 Oct 2014

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.

3 Oct 2014

Schizophrenia and bipolar disorder share common pathophysiological features

Schizophrenia and bipolar disorder both appear to be associated with dendritic spine loss in the brain, suggesting the two distinct disorders may share common pathophysiological features, write author Glenn T. Konopaske, M.D., and colleagues at McLean Hospital, Belmont, Mass., and Harvard Medical School, Boston.

3 Oct 2014

Therapeutics News and Research

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

BIDMC scientists uncover new class of molecules that protects against diabetes

UChicago awarded $12 million grant to establish national center to study drug abuse-related behaviors

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

NIH announces high-risk, high-reward grants for UCSF researchers

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

UCSF researchers receive five NIH awards for high-risk scientific research projects

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

FDA designates NurOwn as Fast Track product for ALS treatment

Many US patients with liver cancer do not receive proper treatment

FDA grants orphan drug designation for neuroblastoma vaccine

SynGen announces securement of additional financing from San Francisco-based life sciences venture capital firm

Halozyme's PEGPH20 receives FDA Orphan Drug designation for treatment of pancreatic cancer

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Schizophrenia and bipolar disorder share common pathophysiological features

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

Dendritic spine density also reduced in bipolar disorder

Placenta-derived cells are safe for MS patients

Allakos secures additional $10M investment to expand its development portfolio

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News